January 10, 2024   USA
sacc-sf.org: Swedish diabetes biotech leader in precision medicine

At the forefront of diabetes research, Diamyd Medical is revolutionizing the treatment of type 1 diabetes by pioneering the world’s first and only gene-based precision medicine confirmatory trial for individuals with Type-1 Diabetes. The phase 3 clinical trial is conducted in Europe and the US, evaluating an antigen-specific approach featuring the protein GAD65, found naturally in the body's insulin-producing cells.

The study is set to conclude in 2026, and the interest in the field is significant indicating a strong willingness among U.S. healthcare practitioners to consider prescribing Diamyd at a potential price range of USD 194,00 - 240,000.

Read the full article here

Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.

Order GAD for preclinical research